A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumours
Objective: The results of treatment of brain tumours have been disappointing. The objective of this study was to evaluate a new treatment with antineoplastons A10 and AS2-1.
Patients and Methods: This study involved a cohort of patients who had failed established therapies and were treated in private practices in the USA and Australia. Patients received daily intravenous injections of antineoplastons A10 and AS2-1 at average dosages of 7.7 and 0.36 g/kg/day, respectively. Tumourdimensions were documented by magnetic resonance imaging. Changes in tumour size were categorised as defined by the National Cancer Institute.
Results: Antineoplastons A10 and AS2-1 eliminated or substantially reduced tumours in 44% of patients with brain tumours. Of the 36 évaluable patients, nine had a complete response, seven a partial response, and 12 stable disease. Progressive disease occurred in eight patients. 15 patients are alive today, 86.5% of them for over 3 years from the beginning of treatment. Complete and partial responses were documented in glioblastoma multiforme, astrocytoma, oligodendroglioma, mixed glioma, medulloblastoma, and malignant meningioma. Adverse drug experiences included easily treated abnormalities in plasma electrolytes. In a small percentage of patients additional adverse effects possibly related to antineoplastons included skin rash (19%), somnolence (17%), weakness (14%), nausea (6%), vomiting (3%), headaches (3%), slurred speech (6%), confusion (3%), fever (3%) and fluid retention (3%). Adverse effects were reversed on temporary discontinuation or dose reduction.
Conclusion: Antineoplaston therapy produced complete or partial responses in 16 of 36 (44%) patients with brain tumours. Compared with standard treatment, antineoplaston therapy is associated with prolonged survival time and prolonged time to disease progression.
Unable to display preview. Download preview PDF.
- 1.Burzynski SR. Purified antineoplaston fractions and methods of treating neoplastic disease. US PatentNo. 4,470,970. 1984Google Scholar
- 2.Burzynski SR. Synthetic antineoplastons and analogs. Drugs Future 1986; 11: 679–88Google Scholar
- 3.Burzynski SR. Potential of antineoplastons in diseases of old age. Drugs Aging 1995; 7(3): 1 7-67Google Scholar
- 5.Burzynski SR, Kubove E, Burzynski B. Phase II clinical trials of Antineoplastons A10 and AS2-1 infusions in astrocytoma. In: Adam D, Buchner T, Rubinstein E, editors. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991: 2506–07Google Scholar
- 6.Burzynski SR, Kubove E, Szymkowski B. Phase II clinical trials of Antineoplastons A10 and AS2-1 infusions in high grade glioma. Presented at the 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2: Stockholm, SwedenGoogle Scholar
- 7.Eriguchi N, Tsuda H, Hara H, et al. The effect of antineoplastons A10, AS2-1 on brain tumors. In: Adam D, Buchner T, Rubinstein E, editors. Recent advances in chemotherapy. Munich: Futuramed Publishers, 1991: 2504–5Google Scholar
- 8.Tsuda H, Sugita Y, Sugita N, et al. Effect of Antineoplaston AS2-1 on high grade glioma. Presented at the 18th International Congress of Chemotherapy; 1993 Jun 27–Jul 2: Stockholm, SwedenGoogle Scholar
- 10.Elias T. The Burzynski Breakthrough. Santa Monica, CA: General Publishing Group; 1997Google Scholar
- 11.Lerner M. Stanislaw Burzynski — antineoplastons on the edge of medical credibility. In: Lerner M, editor. Choices in healing. Cambridge, MA: MIT Press; 1994Google Scholar
- 13.Samid D, Sherman L, Rimoldi D. Induction of phenotypic reversion and terminal differentiation in tumor cells by antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy; 1990 March 26–28, Geneva, SwitzerlandGoogle Scholar
- 20.Liu L, Samid D. Mutant p53 as a target of phenylacetate in human glioblastoma. Presented at the 86th Annual Meeting of the American Association for Cancer Research; 1995 March 18–22; Toronto, CanadaGoogle Scholar
- 29.Prados MD, Chang SM, Malec M, et al. Survival expectation following chemotherapy treatment for patients with GBM and anaplastic glioma (AG) at first relapse: a retrospective review of the UCSF database. Presented at the Society for Neuro-Oncology Meeting; 1999 Jan, San Francisco, CA, USAGoogle Scholar
- 30.60th Meeting of Oncologic Drugs Advisory Committee, FDA; 1999 Jan 12, Gaithersburg, MD, USAGoogle Scholar